Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: A systematic review and meta-analysis of randomized controlled trials

Current Medical Research and Opinion

Volumn 29, Issue 2, 2013, Pages 117-125

  Qi, Wei Xiang ^a   Shen, Zan ^a   Lin, Feng ^a   Sun, Yuan Jue ^a   Min, Da Liu ^a   Tang, Li Na ^a   He, Ai Na ^a   Yao, Yang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Docetaxel; Meta analysis; Metastatic breast cancer; Paclitaxel

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PACLITAXEL;

ANEMIA; AREA UNDER THE CURVE; BREAST METASTASIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; META ANALYSIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS; TREATMENT OUTCOME;

EID: 84872256346     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.756393     Document Type: Review

References (36)

1. Olin JJ, Muss HB. New strategies for managing metastatic breast cancer. Oncology (Williston Park) 2000;14:629-41; discussion 642-4, 647-8
2. Bergh J, Jonsson PE, Glimelius B, et al. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001;40:253-81
3. Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005;104:1742-50
4. El-Saghir JA, El-Habre ET, El-Sabban ME, et al. Connexins: a junctional crossroad to breast cancer. Int J Dev Biol 2011;55:773-80
5. Bria E, Giannarelli D, Felici A, et al. Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma. Cancer 2005;103:672-9
6. Verma S, Dent S, Chow BJ, et al. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev 2008;34:391-406
7. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-17
8. Nabholtz JM, Tonkin K, Smylie M, et al. Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer? Expert Opin Pharmacother 2000;1:187-206
9. Murialdo R, Bertolotti F, Pastorino G, et al. Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial. Cancer Chemother Pharmacol 2011;68:1009-16
10. Mey U, Gorschluter M, Ziske C, et al. Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial. Anticancer Drugs 2003;14:233-8
11. Horiguchi J, Oyama T, Koibuchi Y, et al. Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer. Anticancer Res 2009;29:517-24
12. Lavelle F, Bissery MC, Combeau C, et al. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995;22:3-16
13. Hanauske AR, Degen D, Hilsenbeck SG, et al. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 1992;3:121-4
14. Balzarini A, Pirovano C, Diazzi G, et al. Ultrasound therapy of chronic arm lymphedema after surgical treatment of breast cancer. Lymphology 1993;26:128-34
15. Riou JF, Naudin A, Lavelle F. Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 1992;187:164-70
16. Saloustros E, Mavroudis D, Georgoulias V. Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother 2008;9:2603-16
17. Misso G, Giuberti G, Lombardi A, et al. Pharmacological inhibition of HSP90 and ras activity as a new strategy in the treatment of HNSCC. J Cell Physiol (2013);228:130-41
18. Caraglia M, Giuberti G, Marra M, et al. Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor r115777 in human epithelial cancer cells. Front Biosci 2005;10:2566-75
19. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23:5542-51
20. Khoo KS, Manzoor Zaidi SH, Srimuninnimit V, et al. Gemcitabine and splitdose paclitaxel or docetaxel in metastatic breast cancer: a randomised phase II study. Eur J Cancer 2006;42:1797-806
21. Cassier PA, Chabaud S, Trillet-Lenoir V, et al. A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. Breast Cancer Res Treat 2008;109:343-50
22. Fountzilas G, Dafni U, Dimopoulos MA, et al. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 2009;115:87-99
23. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009;27:3611-19
24. Beuselinck B, Wildiers H, Wynendaele W, et al. Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology. Crit Rev Oncol Hematol 2010;75:70-7
25. Wist EA, Mjaaland I, Lokkevik E, et al. Weekly paclitaxel plus capecitabine versus docetaxel every 3 weeks plus capecitabine in metastatic breast cancer. J Oncol 2012;2012:1-7
26. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352:609-13
27. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform metaanalyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34
28. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005;28:123-37
29. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71
30. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101
31. Gradishar WJKDA, Cheporov SV, Makhson AN, et al. Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Overall survival (OS) subset analyses of a randomized phase 2 trial. J Cancer 2011;47:S348
32. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008;26:1642-9
33. Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004;22:2061-8
34. Mauri D, Kamposioras K, Tsali L, et al. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: a meta-analysis. Cancer Treat Rev 2010;36:69-74
35. Hussain A, Wu Y, Mirmiran A, et al. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy. Int J Radiat Oncol Biol Phys 2012;82:167-74
36. Facchini G, Caraglia M, Morabito A, et al. Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. Cancer Biol Ther 2010;10:543-8